Observational Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Feb 14, 2017; 23(6): 1067-1075
Published online Feb 14, 2017. doi: 10.3748/wjg.v23.i6.1067
Table 1 Demographic data, disease characteristics and medications at the time of the evaluation n (%)
Overall (n = 99)CD (n = 62)UC (n = 37)P value
Gender, females59 (59.6)32 (51.6)27 (73.0)0.063
Age (yr)12.8 ± 2.613.4 ± 2.411.6 ± 2.50.0011
Age at diagnosis (yr)9.9 ± 3.110.7 ± 2.98.6 ± 3.0< 0.0011
Number of hospitalizations42 (1-4)2 (1-4)3 (1-6)0.092
Disease duration at IMPACT completion (yr)2.8 ± 2.62.7 ± 2.53.0 ± 2.70.481
Disease activityNA7.2 ± 10.314.0 ± 20.5NA
Disease status, in remission70 (70.7)45 (72.6)25 (67.6)0.653
Physician global assessment0.93
Clinical remission80 (80.8)50 (80.6)30 (81.1)
Mild14 (14.1)9 (14.5)5 (13.5)
Moderate5 (5.1)3 (4.8)2 (5.4)
Medications at IMPACT completion
Antibiotics2 (2.0)2 (3.2)0 (0.0)0.523
Steroids39 (39.4)24 (38.7)15 (40.5)0.993
Immunomodulators68 (68.7)47 (75.8)21 (56.8)0.113
Biologic agents31 (31.3)25 (40.3)6 (16.2)0.033
Enteral nutrition0 (0.0)0 (0.0)0 (0.0)NA
Aminosalicylates52 (52.5)15 (24.2)37 (100.0)< 0.0013